Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513.

被引：2

作者：

Chiorean, E. Gabriela

McDonough, Shannon

Philip, Philip Agop

Swisher, Elizabeth M.

Pishvaian, Michael J.

Guthrie, Katherine

Lowy, Andrew M.

Hochster, Howard S.

机构：

[1] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[2] Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[3] Karmanos Canc Inst, Detroit, MI USA

[4] Univ Washington, Sch Med, Seattle, WA USA

[5] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[6] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[7] Yale Canc Ctr, New Haven, CT USA

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.TPS4147

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

TPS4147

引用

页数：6